At the Heart of
Cardiac Innovation

About Innoventric

Since its foundation, Innoventric has been committed to addressing the complexities of tricuspid regurgitation
with our transcatheter TR solutions. As leaders in cross-caval technologies, we are dedicated to the ongoing
development of advanced devices to extend the reach of TR treatment. Our approach is rigorously data-driven,
with its roots grounded deep in clinical research. We possess a robust patent portfolio in cross-caval technologies
and are devoted to continuous improvement to enhance patient care for those with structural heart disease. Our
treatments are designed to benefit a broad spectrum of patients, with the aim of making high-quality care more
accessible and improving health outcomes.

Management Team

Scientific Advisory Board

Dr. Stefan Verheye

Dr. Stefan Verheye, MD, PhD, has been a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium since 2000. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. He serves as a member of Scientific Advisory Board of several medical device manufacturers. Dr. Verheye is the author of over 150 peer-reviewed journals (, ten book chapters, over 400 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease, heart failure). He has presented at numerous major conferences such as TCT (Transcatheter Cardiovascular Therapeutics), EuroPCR (European Percutaneous Course on Revascularization), AsiaPCR, AHA (American Heart Association), ACC (American College of Cardiology) and ESC (European Society of Cardiology) and has directed and transmitted several coronary and structural live cases to TCT, EuroPCR and ESC. He served as the medical director for V-Wave, Israel, a medical device company, developing and manufacturing inter-atrial shunt for heart failure. His entrepreneurial interests led to the co-foundation of Hilbert Paradox, NV, a start-up company encompassing a unique way of capturing and correlating digital health data, applying data- and knowledge engineering, which was later on acquired by a large CRO. He co-founded ainthoven, NV, a start-up company dedicated to on-line cardiac signal analytics by exploring the hyperspace of learning algorithms, and recently co-founded Amynas, BV a Belgian based, incorporated technology platform company specializing in nanofiber electrospinning providing anti-infective and anti-inflammatory protection for implanted devices, including CIEDs, neuro-stimulatory and orthopedic devices.
Stefan Verheye graduated from the School of Medicine at the University of Leuven in Belgium and was a resident internal medicine and cardiology both at the University of Aachen, Germany and OLV-Hospital, Aalst, Belgium. After a 2-year fellowship interventional cardiology in Aalst, Belgium, he completed a 2-year period as a research associate and visiting interventional cardiologist at the Andreas Gruentzig Cardiovascular Center at Emory University School of Medicine in Atlanta, Georgia, and served as an affiliate scientist, Division of Molecular Medicine for Yerkes Regional Primate Research Center of Emory University. He earned his PhD at the Department of Pharmaceutical Sciences of the University of Antwerp.

Dr. Bill Abraham

Dr. Abraham earned his medical degree from Harvard Medical School, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. He previously held leadership positions at the University of Colorado, the University of Cincinnati, the University of Kentucky, and the Ohio State University. At Ohio State, Dr. Abraham held several leadership positions, including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio. As Division Director from October 2002 until January 2019, Dr. Abraham developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S. As a noted heart failure specialist, Dr. Abraham has been recognized as one of the “Best Doctors in America” for 20 consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction. Dr. Abraham is recognized as an international leader in heart failure research. His research has contributed to the approval/adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, ultrafiltration, cardiac resynchronization therapy, implantable hemodynamic monitoring devices, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and transcatheter mitral valve repair. Dr. Abraham has authored over 1,500 original papers, abstracts, book chapters, and review articles. He serves as series editor for the "Color Atlas and Synopsis of Cardiovascular Medicine." He has been named to the Clarivate Analytics Highly Cited Researchers list, ranking him among the top 1% most cited researchers for his subject field, and recognized as one of The World’s Most Influential Scientific Minds. In 2017, Dr. Abraham was the recipient of the American College of Cardiology Distinguished Scientist Award. In 2022, Dr. Abraham received the Pioneer Award from the Heart Failure Society of America. In addition to his clinical and scholarly activities, Dr. Abraham serves as chief medical officer at V-Wave and as a consultant to companies involved in new drug and device development for heart failure.

Clinical Collaborations

Skip to content